Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Biochemical and Biophysical Research Communications
|
April 26, 2011
Protein kinase A activates and phosphorylates RORα4 in vitro and takes part in RORα activation by CaMK-IV
Michael Ermisch, Beate Firla, Dieter Steinhilber
Biological Chemistry
|
November 5, 2011
Dimerization of human 5-lipoxygenase
Ann-Kathrin Häfner, Mihaela Cernescu, Bettina Hofmann, et al.
Journal of Market Access & Health Policy
|
February 24, 2025
Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy
Elaine Julian, Tom Belleman, Maria João Garcia, et al.
Applied Health Economics and Health Policy
|
November 8, 2019
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
Caridad Pontes, Corinne Zara, Josep Torrent-Farnell, et al.
Frontiers in Pharmacology
|
October 14, 2016
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
Michael Ermisch, Anna Bucsics, Patricia Vella Bonanno, et al.
Frontiers in Pharmacology
|
September 8, 2017
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
Patricia Vella Bonanno, Michael Ermisch, Brian Godman, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Biochemical and Biophysical Research Communications
|
April 26, 2011
Protein kinase A activates and phosphorylates RORα4 in vitro and takes part in RORα activation by CaMK-IV
Michael Ermisch, Beate Firla, Dieter Steinhilber
Biological Chemistry
|
November 5, 2011
Dimerization of human 5-lipoxygenase
Ann-Kathrin Häfner, Mihaela Cernescu, Bettina Hofmann, et al.
Journal of Market Access & Health Policy
|
February 24, 2025
Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy
Elaine Julian, Tom Belleman, Maria João Garcia, et al.
Applied Health Economics and Health Policy
|
November 8, 2019
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
Caridad Pontes, Corinne Zara, Josep Torrent-Farnell, et al.
Frontiers in Pharmacology
|
October 14, 2016
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
Michael Ermisch, Anna Bucsics, Patricia Vella Bonanno, et al.
Frontiers in Pharmacology
|
September 8, 2017
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
Patricia Vella Bonanno, Michael Ermisch, Brian Godman, et al.
Page
of 1